Friends Or Foes? The Changing Regulator/Industry Relationship In Europe
This article was originally published in SRA
Recent years have seen the pharmaceutical industry working more closely with European regulators as the nature of drug development changes, with companies increasingly being urged to engage at an ever earlier stage with regulatory agencies and health technology assessment bodies to discuss their development programs.
Register for our free email digests: